Find information on smoldering myeloma diagnosis, including clinical documentation requirements, ICD-10 codes (C90.00, C90.01, C90.02), medical coding guidelines, and healthcare resources. Learn about the diagnostic criteria, staging, and management of smoldering multiple myeloma for accurate reporting and improved patient care. Explore resources for healthcare professionals on differentiating smoldering myeloma from active multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS). This resource provides guidance on proper documentation and coding for smoldering myeloma to ensure appropriate reimbursement and facilitate clinical research.
Also known as
Multiple myeloma
Includes indolent myeloma, requiring monitoring but not treatment.
Monoclonal gammopathy
Covers MGUS, a precursor that may evolve into myeloma.
Other general symptoms
May be used for nonspecific symptoms before a firm diagnosis.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Smoldering Myeloma?
When to use each related code
| Description |
|---|
| Smoldering Myeloma |
| Monoclonal Gammopathy of Undetermined Significance (MGUS) |
| Multiple Myeloma |
Smoldering myeloma (C90.02) can be miscoded as monoclonal gammopathy of undetermined significance (MGUS, D47.2) due to similar features, impacting reimbursement and quality metrics.
Lack of documentation specifying CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) can lead to undercoding of active myeloma instead of smoldering myeloma.
Missing or inaccurate documentation of smoldering myeloma stage, specifically if ISS stage is available, impacts risk stratification and treatment planning, leading to inaccurate coding.
Patient presents with a suspected diagnosis of smoldering multiple myeloma (SMM). Review of systems reveals no CRAB criteria (hypercalcemia, renal insufficiency, anemia, or bone lesions). Specifically, calcium levels are within normal limits, serum creatinine is unremarkable, hemoglobin is stable, and skeletal survey or MRI of the spine and pelvis shows no lytic lesions or evidence of bone disease. However, laboratory findings indicate monoclonal protein in the serum or urine exceeding the diagnostic threshold for SMM (serum M-protein greater than or equal to 3 g/dL, or urine M-protein greater than or equal to 500 mg/24 hours) andor bone marrow plasma cell infiltration between 10% and 60%. Free light chain ratio is abnormal. The patient is currently asymptomatic and no treatment is indicated at this time. Plan includes close monitoring with regular follow-up visits, including serum and urine protein electrophoresis, free light chain assay, complete blood count, and calcium levels. Patient education provided regarding the nature of smoldering myeloma, its potential progression to active multiple myeloma, and the importance of adherence to the monitoring schedule. Differential diagnosis includes monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma, but the current clinical and laboratory findings support the diagnosis of smoldering multiple myeloma. The patient understands the need for ongoing surveillance for disease progression and development of symptoms requiring therapeutic intervention. ICD-10 code D47.1, smoldering multiple myeloma, is assigned.